A clinican's guide to adult attention-deficit hyperactivity disorder

Connecticut Medicine

Volumn 76, Issue 9, 2012, Pages 517-523

  Modesto Lowe, Vania ^a   Meyer, Andrea ^b   Soovajian, Victoria ^c  

^a Young Adult Services   (United States)

^b QUINNIPIAC UNIVERSITY   (United States)

^c Valley Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT;

ARTICLE; ATTENTION DEFICIT DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMAN; PRACTICE GUIDELINE; PSYCHOLOGIC TEST; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSYCHOLOGICAL TESTS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84868004998     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Wilens TE: ADHD: Prevalence, diagnosis and issues of comorbidity. CNS Spectr 2007; 12( 4): 3-5.
2. Kessler RC, Adler L, Barkley R, et al: The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication Am J Psychiatry 2006; 163:716-23. (Pubitemid 44464584)
3. Fayyad J, De Graaf R, Kessler R, et al: Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Brit J Psychiatry 2007; 190: 402-9.
4. McGough JJ, Smalley SL, McCracken JT, et al; Psychiatric comorbidity in adult attention deficit hyperactivity disorder: Findings from multiplex families. Am J Psychiatry 2005; 162(9):1621-7. (Pubitemid 41318230)
5. Wilens TE, Biederman J, Spencer TJ: Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med 2002; 53:113-31. (Pubitemid 34177874)
6. Biederman J, Faraone SV, Spencer TJ, et al: Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community./ Clin Psychiatry 2006; 67(4):524-40. (Pubitemid 43764229)
7. Adler LA, Barker RA, Newcorn JH: Performance improvement CME: Adult ADHD. J Clin Psychiatry 2011; 72( 4): el5.
8. Hinshaw SP, Scheffler RM, Fulton BD, et al: International variation in treatment procedures for ADHD: Social context and recent trends. Psychiatr Serv 2011; 62( 5): 459-64.
9. Haavik J, Halmoy A, Lundervold AJ, Fasmer OB: Clinical assessment and diagnosis of adults with attention-deficit/hyperactivity disorder. Expert Rev Neurther 2010; 1569-80.
10. Barkley RA, Brown TE: Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorder. CNS Spectr 2008; 13( 11): 977-84.
11. Culpepper L, Mattingly G: Challenges in identifying and managing attention-deficit/hyperactivity disorder in adults in the primary care setting: A review of the literature. Prim Care Companion J Clin Psychiatry 2010; 12( 6): pii: PCC.10r00951.
12. Jardin B, Looby A, Earleywine M: Characteristics of college students with attention-deficit hyperactivity disorder symptoms who misuse their medications. J Am Coll Health 2011; 59( 5): 373-7.
13. Schelleman H, Bilker WB, Strom BL, et al: Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011; 127( 6): 1102-10.
14. Goodman DW, Lasser RA, Babcock T, et al: Managing ADHD across the lifespan in the primary care setting. Postgrad Med 2011; 123( 5): 14-26.
15. Taylor A, Deb S, Unwin G: Scales for the identification of adults with attention deficit hyperactivity disorder (ADHD): A systematic review. Res Dev Disabil 2011; 32( 3): 924-38.
16. Modesto-Lowe V, Danforth JS, Neering C: Easton C: Can we prevent smoking in children with ADHD: A review of the literature. Conn Med 2010; 74( 4): 229-36.
17. Barkley RA, Fischer M: Predicting impairment in major life activities and occupational functioning in hyperactive children as adults: Self-reported executive function (EF) deficits versus EF tests. Dev Neuropsychol 2011; 36( 2): 137-61.
18. Braek D, Dijkstra JB, Jolies J: Cognitive complaints and neuropsychological functioning in adults with and without attention-deficit hyperactivity disorder referred for multidisciplinary assessment. Appl Neuropsychol 2011; 18( 2): 127-35.
19. Gaultieri CT: A practical approach to objective attention deficit/hyperactivity disorder diagnosis and management. Psychiatry 2005; 2( 7): 17-25.
20. Hervey AS, Epstein JN, Curry JF: Neuropsychology of adults with attention-deficit/hyperactivity disorder: A meta-analytic review. Neuropsychology 2004; 18:485-503. (Pubitemid 38944385)
21. Spencer TJ, Biederman J, Mick E: Attention-deficit/hyperactivity disorder: Diagnosis, lifespan, comorbidities, and neurobiology. Ambul Pediatr 2007; 7( 1 Suppl): 73-81.
22. Klassen LJ, Katzman MA, Chokka P: Adult ADHD and its comorbidities, with a focus on bipolar a focus on biplar disorder. J Affect Disord 2010; 124( 1- 2): l-8.
23. CADDRA Guidelines Steering Committee. Canadian ADHD practice guidelines: CADDRA 2008. Canadian ADHD/ADD Resource Alliance Web site. http://www. naceonline.com/AdultADHDtoolkit/professionalresources/ caddraguidelines.pdf. Accessed 20 Dec 2011.
24. Wilens TE, Morrison NR, Prince J: An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother 2011; 11( 10): 1443-65.
25. Hammerness P, Surman C, Miller K: Update on adult attention-deficit/ hyperactivity disorder. Curr Neurol Neurosci Rep 2008; 8( 6): 484-9.
26. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW: The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011; 69( 12): el45-el57.
27. Heal DJ, Smith SL, Findling RL: ADHD: Current and future therapeutics. Curr Top Bekav Neurosci 2011. doi: 10.1007/7854-2011-125
28. Arnsten AF: Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: An important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23( Suppl 1): 33-41.
29. Arnsten AF: Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry. 2011; 69( 12): e89-99.
30. Ramos-Quiroga JA, Corominas M, Castells X, Bosch R, Casas M. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disoider. Expert Rev Neurother 2009; 9( 8): 1121-31.
31. McBurnett K, Starr HL: OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder. Expert Opin Pharmacother. 2011; 12( 2): 315-324.
32. Adler LA, Zimmerman B, Starr HL, et al: Efficacy and safety of OROS methylphenidate in adults with attention-deficit/ hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009; 29( 3): 239-47.
33. SpencerTJ, Adler LA, McGough JJ, et al: Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007; 61(12):1380-7. (Pubitemid 46855767)
34. Moen MD, Keam SJ: Dexmethylphenidate extended release: A review of its use in the treatment of attention-deficit hyperactivity disorder. CNSDrugs 2009; 23( 12): 1057-83.
35. McGough JJ, Pataki CS, Suddath R: Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder. Expert Rev Neurother 2005; 5(4):437-41. (Pubitemid 41021049)
36. Biederman J, Spencer TF, Wilens TE, et al: Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 2005; 10(12 Suppl 20):16-25. (Pubitemid 43010494)
37. Faraone SV: Stimulant therapy in the management of ADHD: Mixed amphetamine salts (extended release). Expert Opin Pharmacother 2007; 8( 13): 2127-34.
38. McKeage K, Scott LJ: SLI-381 (adderall XR). CNS Drugs 2003; 17( 9): 669-77.
39. Najib J: The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clin Ther 2009; 31( 1): 142-76.
40. Goodman DW: Lisdexamfetamine dimesylate (Vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. PT 2010; 35( 5): 273-6,282-7.
41. Simpson D, Plosker GL: Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs 2004; 18( 6): 397-401.
42. Sobanski E, Sabljic D, Aim B, et al: A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 2011; doi: 10.1055/s-00311291319.
43. Garnock-Jones KP, Keating GM: Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents. PaediatrDrugs 2009; 11( 3): 203-26.
44. Marchant BK, Reimherr FW, Halls C, et al: Long-term openlabel response to atomoxetine in adult ADHD: Influence of sex, emotional dysregulation, and double-blind response to atomoxetine. Atten Defic Hyperact Disord 2011; 3( 3): 237-44.
45. Sansone RA, Sansone LA: Faking attention deficit hyperactivity disorder. Innov Clin Neurosci 2011; 8( 8): 10-13.
46. Dart RC: Monitoring risk: Post marketing surveillance and signal detection. Drug Alcohol Depend 2009; 105( Suppl 1): S26-32.
47. Rabiner DL, Anastopoulos AD, Costello EJ, et al: Themisuse and diversion of prescribed ADHD medications by college students. J Atten Disord 2009; 13( 2): 144-53.
48. DeSantis AD, Webb EM, Noar SM: Illicit use of prescription ADHD medications on a college campus: A multimethodological approach. J Am Coll Health 2008; 57( 3): 315-24.
49. Rogers PD, Copley L: The nonmedical use of prescription drugs by adolescents. Adlesc Med State Art Rev 2009; 20( 1): l-8.
50. Frauger E, Pauly V, Natali F, et al: Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: Main trends from 2005-2008. CNS Drugs 2011; 25( 5): 415-24.
51. Wright C, Schnoll S, Bernstein D: Risk evaluation and mitigation strategies for drugs with abuse liability: Public interest, special interest, conflicts of interest, and the industry perspective. Ann NYAcad Sci 2008; 1141: 284-303.
52. Kasi PM, Mounzer R, Gleeson GH: Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system. Cast Report Med 2011; 2011: 952584.
53. Habel LA, Cooper WO, Sox CM, et al: ADHD medications and risk of serious cardiovascular events in young and middleaged adults. JAMA 2011; doi: 10.1001/jama.2011.1830
54. Cooper WO, Habel LA, Sox CM, et al: ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365( 20): 1896-904.
55. Graham J, Banaschewski T, Buitelaar J, et al: European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011; 20( 1): 17-37.
56. Kraemer M, Uekermann J, Wiltfang J, Kis B: Methylphenidateinduced psychosis in adult attention-deficit/hyperactivity disorder: Report of three new cases and review of the literature. Clin Neuropharmacol 2010; 33( 4): 204-6.
57. Knouse LE, Cooper-Vince C, Sprich S, Safren SA. Recent developments in the psychosocial treatment of adult ADHD. Expert Rev Neurother 2008; 8( 10): 1537-1548.
58. Safren SA, Sprich S, Mimiaga MJ, et al: Cognitive behavioral therapy vs relaxation with educational support for medicationtreated adults with ADHD and persistent symptoms: A randomized controlled trial. JAMA 2010; 304( 8): 875-80.
59. Young S, Amarasinghe JM: Practitioner review: Nonpharmacological treamtnets for ADHD: A lifespan approach. J Child Psychol Psychiatry 2010; 51( 2): 116-33.
60. Safren SA: Cognitive-behavioral approaches to ADHD treatment in adulthood. Clin Psychiatry 2006; 67( Suppl 8): 46-50.
61. KubikJA: Efficacy of ADHD coaching for adults with ADHD. J Atten Disord 2010; 13( 5): 442-53.
62. Zwart LM, Kallemyn LM: Peer-based coaching for college students with ADHD and learning disabilities. J Postsecondary EducDisabil 2001; 15: 1-15.
63. Philipsen A, Graf E, Tebartz van Eist L, et al: Evaluation of the efficacy and effectiveness of a structured disorder tailored psychotherapy in ADHD in adults: Study protocol of a randomized controlled multicentre trial. Atten Defic Hyperact Disord 2010; 2( 4): 203-12.
64. Hirvikoski T, Waaler E, Alfredsson J, et al: Reduced ADHD symptoms in adults with ADHD after structured skills training group: Results from a randomized controlled trial. Behav Res Ther 2011; 49( 3): 175-85.
65. Zylowska L, Ackerman DL, Yang MH, et al: Mindfulness meditation training in adults and adolescents with ADHD: A feasibility study. Atten Disord 2008; 11( 6): 737-46.